We observed KRAS driven toxicity in multiple cancer types, and with different KRAS mutant alleles, including through ectopic expression of KRASG12C in H358, H23, and H1792 cells, and of KRASG12D in HCT 116 cells, which lead to decreased cell viability in all instances (Fig. 5F–K and Supplementary Fig. S5J). Here, KRAS is linked to cancer.